AndreaBozzo/ceres-open-data-index huggingface dataset:
Compound 526561: 3-Ethenyl-2,5-dimethylpyrazine

Chemical compound data from PubChem database. IUPAC Name: 3-ethenyl-2,5-dimethylpyrazine. Molecular Formula: C8H10N2. Molecular Weight: 134.18. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Dose response of ACE inhibitors: implications of the SECURE trial

The choice of the appropriate dosage of ACE inhibitor in clinical practice is an important one. The available evidence suggests that in chronic heart failure as well as in chronic coronary artery disease, high doses of angiotensin-converting enzyme (ACE) inhibitor are more effective than low ones. The current recommended clinical approach is to target ACE inhibitor dosing regimens to be similar to those used in the clinical trials, which demonstrated mortality and morbidity benefits. When titrated appropriately, ACE inhibitors are generally well tolerated and target doses can be achieved and maintained in the majority of patients with atherosclerotic vascular disease, with or without heart failure.
Mouse skin passage of a Streptococcus pyogenes Tn917 mutant of sagA/pel restores virulence, beta-hemolysis and sagA/pel expression without altering the position or sequence of the transposon: Correction

Mouse skin passage of a Streptococcus pyogenes Tn917 mutant of sagA/pel restores virulence, beta-hemolysis and sagA/pel expression without altering the position or sequence of the transposon: Correction
Debate: "How low should LDL cholesterol be lowered for optimum prevention of vascular disease?" Viewpoint: "Below 100 mg/dl"

Arteriosclerotic vascular disease manifests as heart disease, stroke, aortic aneurysms, and peripheral vascular disease, and is a growing problem world-wide. The preventive efforts made so far have demonstrated that lowering LDL-C is one action that individuals and populations can do with significant success in delaying the onset of clinical events. Epidemiological studies and small clinical trials suggest that more aggressive and sustained lowering to LDL-C below 100 mg/dl could result in 50 to 70% reductions in vascular death. The full benefit of reducing LDL-C is only now being tested in adequate clinical trials.
Glyburide and metformin hydrochloride

Glyburide and Metformin Hydrochloride is a prescription oral tablet combining two diabetes medications: glyburide (a sulfonylurea) and metformin (a biguanide). It helps control blood sugar in adults with type 2 diabetes. Available in strengths like 1.25mg/250mg, 2.5mg/500mg, and 5mg/500mg. Manufactured by Zydus Pharmaceuticals. This information was generated using AI and is provided for informational and research purposes only.
NCHS Research and Development Survey (RANDS) Round 1 during COVID-19 probability sampled Restricted File

The Research and Development Survey (RANDS) is a series of cross-sectional surveys from probability-sampled commercial survey panels. As part of a special iteration of RANDS that focuses on COVID-19, RANDS during COVID-19 Round 1 is the first round of a three-round survey. The probability sample of RANDS during COVID-19 Round 1 was recruited using NORC at the University of Chicago (NORC)'s AmeriSpeak Panel, and the survey was administered by NORC from June 9, 2020 to July 6, 2020. The RANDS during COVID-19 Round 1 Probability Sample has a known survey sampling design and can be used to produce nationally and sub-nationally representative estimates.
Compound 525662: p-Bromobenzylidene-(4-methoxyphenyl)-amine

Chemical compound data from PubChem database. IUPAC Name: 1-(4-bromophenyl)-N-(4-methoxyphenyl)methanimine. Molecular Formula: C14H12BrNO. Molecular Weight: 290.15. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Compound 525873: N,N-Dimethyl-N'-(3-chlorophenyl)-pivalamidine

Chemical compound data from PubChem database. IUPAC Name: N'-(3-chlorophenyl)-N,N,2,2-tetramethylpropanimidamide. Molecular Formula: C13H19ClN2. Molecular Weight: 238.75. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Cosibelimab

UNLOXCYT (cosibelimab) is a monoclonal antibody that blocks PD-L1 to help the immune system fight cancer cells. It's given as an intravenous injection, with each vial containing 300 mg in 5 mL. Manufactured by Checkpoint Therapeutics, Inc., it's approved for prescription use. This information was generated using AI and is provided for informational and research purposes only.
Compound 526014: m-Octopamine, DTFMB-TMS

Chemical compound data from PubChem database. IUPAC Name: 3,5-bis(trifluoromethyl)-N-[2-trimethylsilyloxy-2-(3-trimethylsilyloxyphenyl)ethyl]benzamide. Molecular Formula: C23H29F6NO3Si2. Molecular Weight: 537.6. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Compound 526188: 2-Formyl-5-methyl-4,5-dihydrothiophene

Chemical compound data from PubChem database. IUPAC Name: 2-methyl-2,3-dihydrothiophene-5-carbaldehyde. Molecular Formula: C6H8OS. Molecular Weight: 128.19. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Compound 526825: 15-Hydroxy-arachidic, methyl ester, tBDMS ether

Chemical compound data from PubChem database. IUPAC Name: methyl 15-[tert-butyl(dimethyl)silyl]oxyicosanoate. Molecular Formula: C27H56O3Si. Molecular Weight: 456.8. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Elosulfase alfa

VIMIZIM (elosulfase alfa) is an injectable enzyme replacement therapy used to treat Mucopolysaccharidosis Type IVA (Morquio A syndrome), a rare genetic disorder. It works by providing the missing enzyme to break down certain sugars in the body. Administered intravenously by a healthcare professional, it's available as a 5 mg/5 mL solution. Manufactured by BioMarin Pharmaceutical Inc. This information was generated using AI and is provided for informational and research purposes only.
Bumetanide

Bumetanide is a prescription loop diuretic that helps remove excess fluid from the body by increasing urine production at the kidneys' loop of Henle. Available as oral tablets in 0.5 mg, 1 mg, and 2 mg strengths, it's manufactured by Taro Pharmaceuticals U.S.A., Inc. This information was generated using AI and is provided for informational and research purposes only.
Oregon (OR)

This report presents estimates for measures of substance use and mental health based on the combined 2010 and 2011 National Surveys on Drug Use and Health (NSDUHs). Topics covered include past month substance use (e.g., illicit drugs, marijuana, cocaine, pain relievers, alcohol, tobacco), substance dependence, abuse, and treatment need, past year serious mental illness (SMI), any mental illness (AMI), suicidal thoughts, and major depressive episode (MDE). Resuts are provided for Oregon for five age groups: 12 to 17, 18 to 25, 26 or older, 18 or older and all persons 12 or older.
Value Modifier

The Medicare Value-Based Payment Modifier (Value Modifier) data contains the performance results of de-identified practices that were subject to the Value Modifier, such as the practices' quality and cost tiers along with any applicable Value Modifier payment adjustment. The Value Modifier provided for differential payment under the Medicare Physician Fee Schedule based on the quality of care furnished to Medicare beneficiaries compared to the cost of care during a performance period. Calendar Year 2015 was the first payment adjustment period under the Value Modifier based on performance in 2013. Calendar Year 2018 was the final payment adjustment period under the Value Modifier based on performance in 2016.
Compound 526370: 1,2,4,6,7,9-Hexabromo-dibenzo-dioxin

Chemical compound data from PubChem database. IUPAC Name: 1,2,4,6,7,9-hexabromodibenzo-p-dioxin. Molecular Formula: C12H2Br6O2. Molecular Weight: 657.6. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Engaging Fathers Part 3

This Child Welfare Information Gateway Podcast is available on Apple Podcasts
  
  

, GooglePlay
  
  

, Spotify
  
  

, Stitcher
  
  

, SoundCloud
  
  

, and the Child Welfare Information Gateway
  
  

 website. Subscribe to receive new episodes as they are released.

Metadata-only record linking to the original dataset. Open original dataset below.
Compound 530759: 2,6-Difluorobenzoic acid, 2-chlorophenyl ester

Chemical compound data from PubChem database. IUPAC Name: (2-chlorophenyl) 2,6-difluorobenzoate. Molecular Formula: C13H7ClF2O2. Molecular Weight: 268.64. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Plan ID Crosswalk PUF - PY2015

The Plan ID Crosswalk PUF (CW-PUF) is one of the seven files that make up the Marketplace PUF. The purpose of the CW-PUF is to map QHPs and SADPs offered through the Marketplaces in 2014 to plans that will be offered through the Marketplaces in 2015. These data either originate from the Plan Crosswalk template (i.e., template field), an Excel-based form used by issuers to describe their plans in the QHP application process, or were generated by CCIIO for use in data processing (i.e., system-generated).This data dictionary describes the variables contained in the CW-PUF. Each record relates to a mapping between a plan offered in 2014 and a plan offered in 2015 at the county or county-zip code level.
Impact of false-positive mammography on subsequent screening attendance and risk of cancer

Background
          One area of concern within the largely successful UK National Health Service breast screening programme is the relatively high proportion of women showing mammographic abnormalities who undergo further diagnostic tests that prove negative. Previous studies suggest that, in addition to increasing anxiety, such false-positive mammography is associated with increased risk of subsequent interval cancer. In the present article, we quantify this increased risk, investigate whether it extends to cancers detected at rescreening, and determine whether cancers differ between women who have, and have not, experienced false-positive mammography.
        
        
          Methods
          This was a retrospective cohort study of 140,387 women aged 49–63 years routinely invited for first screening by the East Anglian National Health Service breast screening programme. Proportions reattending, and subsequent risk and pathological attributes of cancer were compared between women who underwent further (negative) assessment following false-positive mammography and women mammographically normal at first screen.
        
        
          Results
          At first screen, 108,617 (91.9%) of the screened women were mammographically normal, 4278 (3.6%) were assessed and then judged normal, and 514 (0.4%) underwent benign biopsy. Compared with nonassessed normal women, reattendance was lower among assessed women: 83.1% (95% confidence interval [CI], 82.0–84.1) versus 85.7% (95% CI, 85.5–85.9) (odds ratio [OR], 0.82; 95% CI, 0.76–0.89). Assessed women were at greater risk of interval cancer (rate per 1000 women screened, 9.6 [95% CI, 6.8–12.4] versus 3.0 [95% CI, 2.7–3.4]; OR, 3.19 [95% CI, 2.34–4.35]), and also of cancer detected at second screen (rate per 1000, 8.4 [95% CI, 5.8–10.9] versus 3.9 [95% CI, 3.5–4.3]; OR, 2.15 [95% CI, 1.55–2.98]). More cancers in assessed women measured ≥ 20 mm (OR, 1.59; 95% CI, 0.99–2.55).
        
        
          Conclusions
          Women undergoing false-positive mammography at first screen were less likely to reattend for subsequent screens than were nonassessed women, yet they were more likely to develop interval cancers or cancers at second screen, and their cancers were larger. Factors predisposing for false-positive mammography require investigation. Women should be encouraged to continue with screening.
Weekly Cumulative Updated 2023-24 COVID-19 Vaccination Coverage, by Race and Ethnicity, Medicare Fee-For-Service Beneficiaries aged ≥65 years, United States, Data Source: Centers for Medicare & Medicaid Services Chronic Conditions Warehouse

Weekly Cumulative Updated 2023-24 COVID-19 Vaccination Coverage, by Race and Ethnicity, Medicare Fee-For-Service Beneficiaries aged ≥65 years 

• Estimated COVID-19 vaccination coverage among Medicare fee-for-service beneficiaries >65 years is assessed using data files from the Medicare Fee-For-Service (FFS) administrative claims data managed by the Centers for Medicare & Medicaid Services (CMS).

• Starting in September 2023, the CDC recommended the 2023-2024 updated COVID-19 vaccine to protect against serious illness from COVID-19. (https://www.cdc.gov/coronavirus/2019-ncov/vaccines/stay-up-to-date.html)
Miscellaneous Tables (Standard Errors and P Values) - 6.1 to 6.107

These detailed tables present the standard errors for the totals and prevalence estimates of the number of days and types of substance use, poly-drug use, nicotine dependence, substance dependence by age of first use, source of substances, social context of substance use, and drunk/drugged driving from the 2012 National Survey on Drug Use and Health (NSDUH). Substances examined include illicit drugs, marijuana, cocaine, heroin, hallucinogens, inhalants, and the nonmedical use of prescription-type pain relievers, tranquilizers, stimulants, and sedatives, and alcohol. Standard errors are provided for totals and prevalence estimates of lifetime, past year, and past month use by age group, gender, race/ethnicity, education level, employment status, geographic area, pregnancy status, college enrollment status, and probation/parole status. Comparisons are made between 2012 and 2011.
Prenatal diagnosis of Neu-Laxova syndrome: a case report

Background
          Neu-Laxova syndrome is a rare congenital abnormality involving multiple systems. We report a case of Neu-Laxova syndrome (NLS) diagnosed prenatally by ultrasound examination.
        
        
          Case presentation
          A 29-year-old gravida 3, para 2 woman was first seen in our antenatal clinic at 38 weeks' pregnancy. Except for the consanguinity and two previous abnormal stillborn babies her medical history was unremarkable. On ultrasound examination microcephaly, flat forehead, micrognathia, intrauterine growth restriction, generalized edema of the skin, hypoplastic chest, excessive soft tissue deposition of hands and feet, joint contractures and a penis without scrotal sacs were detected. She delivered a 2000 g male fetus. He died five minutes after delivery. Postmortem examination confirmed the diagnosis of Neu-Laxova syndrome.
        
        
          Conclusion
          Because of the autosomal recessive inheritance of Neu-Laxova syndrome genetic counseling and early-serial ultrasound examination should be performed at risk families. Early diagnosis of the disease may offer termination of the pregnancy as an option.
Compound 526545: 2-(Diethylamino)ethyl 3,3-diphenylpropanoate

Chemical compound data from PubChem database. IUPAC Name: 2-(diethylamino)ethyl 3,3-diphenylpropanoate. Molecular Formula: C21H27NO2. Molecular Weight: 325.4. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Compound 528572: tert-Butyl(dimethyl)silyl decanoate

Chemical compound data from PubChem database. IUPAC Name: [tert-butyl(dimethyl)silyl] decanoate. Molecular Formula: C16H34O2Si. Molecular Weight: 286.52. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Compound 526956: ortho,meta'-alpha-Hydroxydinitrodiphenylacetic acid, methyl ester

Chemical compound data from PubChem database. IUPAC Name: methyl 2-hydroxy-2-(2-nitrophenyl)-2-(3-nitrophenyl)acetate. Molecular Formula: C15H12N2O7. Molecular Weight: 332.26. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Compound 525342: 2,2,4,4-Tetramethyl-3-thiahexane

Chemical compound data from PubChem database. IUPAC Name: 2-tert-butylsulfanyl-2-methylbutane. Molecular Formula: C9H20S. Molecular Weight: 160.32. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Compound 529529: Methyl (2E)-2-(5,7-ditert-butyl-1,3-benzoxathiol-2-ylidene)-3,3,3-trifluoropropanoate

Chemical compound data from PubChem database. IUPAC Name: 1,3-difluorophenanthrene. Molecular Formula: C14H8F2. Molecular Weight: 214.21. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Patent AT-E400870-T1: [Translated] METHOD AND SYSTEM FOR CLASSIFYING AN AUDIO SIGNAL

The invention describes a method of classifying an audio input signal ( 1 ), said method comprising the steps of extracting a number of features ( 2 ) of the audio input signal ( 1 ), deriving a feature vector ( 3 ) for the input audio signal ( 1 ) based on these features ( 2 ), and determining the probability that the feature vector ( 3 ) for the input audio signal ( 1 ) falls within any of a number of classes (C 1 , C 2 , . . . , Cn), each corresponding to a particular release-date information.
Kentucky: 2011-2012 NSDUH

This report presents Kentucky\'s estimates for 25 measures of substance use and mental health based on the combined 2011 and 2012 National Surveys on Drug Use and Health (NSDUHs). Topics covered include past month substance use (e.g., illicit drugs, marijuana, cocaine, pain relievers, alcohol, tobacco), substance dependence, abuse, and treatment need, past year serious mental illness (SMI), any mental illness (AMI), suicidal thoughts, and major depressive episode (MDE). Resuts are provided by State and for five age groups: 12 to 17, 18 to 25, 26 or older, 18 or older and all persons 12 or older.
Compound 526093: Tetracosanoic acid, 22-methyl, trimethylsilyl ester

Chemical compound data from PubChem database. IUPAC Name: trimethylsilyl 22-methyltetracosanoate. Molecular Formula: C28H58O2Si. Molecular Weight: 454.8. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
State Panel Discussion on Education Data Exchange

In this presentation, the Children's Bureau hosted a state panel discussion on building and maintaining data exchanges between education and child welfare information systems. This discussion included a description and background of the data exchanges for Kentucky, New York, New York City, and Wisconsin. Topics discussed included data security and use, maintaining and enhancing the data exchange, and lessons learned.

The speakers for this panel were:

Metadata-only record linking to the original dataset. Open original dataset below.
Genetic epidemiology: Psoriatic arthritis

The existence of psoriatic arthritis as a distinct clinical entity remains a topic of debate; some authors propose that it is simply the co-occurrence of psoriasis and inflammatory arthritis. However, a distinct entity is likely to have distinct susceptibility factors in addition to those that contribute to psoriasis and inflammatory arthritis alone. These aetiological factors may be genetic and/or environmental, and in this review, the evidence for distinct psoriatic arthritis genetic susceptibility factors is considered.
Publications Using SAMHSA DataGeorgia: 2011-2012 NSDUH

This report presents Georgia\'s estimates for 25 measures of substance use and mental health based on the combined 2011 and 2012 National Surveys on Drug Use and Health (NSDUHs). Topics covered include past month substance use (e.g., illicit drugs, marijuana, cocaine, pain relievers, alcohol, tobacco), substance dependence, abuse, and treatment need, past year serious mental illness (SMI), any mental illness (AMI), suicidal thoughts, and major depressive episode (MDE). Resuts are provided by State and for five age groups: 12 to 17, 18 to 25, 26 or older, 18 or older and all persons 12 or older.
Pleasure in decision-making situations

Background
          This study explores the role of pleasure in decision making.
        
        
          Results
          In Experiment 1, 12 subjects were presented with a questionnaire containing 46 items taken from the literature. Twenty-three items described a situation where a decision should be made and ended with a suggested solution. The other items served as filler items. The subjects were requested not to make a decision but to rate the pleasure or displeasure they experienced when reading the situation described in the item. The subjects' ratings were then compared to the decisions on the same situations made by the other subjects of the studies published by other workers. The ratings of pleasure/displeasure given by our subjects correlated significantly with the choices published by other authors. This result satisfies a necessary condition for pleasure to be the key of the decision making process in theoretical situations. In Experiment 2, a new group of 12 subjects rated their experience of pleasure/displeasure when reading various versions of 50 situations taken from daily life where an ethical decision had to be made (Questionnaire I) including 200 items. This was followed by a multiple-choice test with the 50 situations (Questionnaire II) using the same 200 items and offering the various behaviors. Subjects tended to choose ethical and unethical responses corresponding to their highest pleasure rating within each problem. In all cases the subjects' behavior was higher than chance level, and thus, followed the trend to maximize pleasure. In Experiment 3, 12 subjects reading 50 mathematical short problems followed by correct and incorrect versions of the answer to the problem (Questionnaire III), including 200 items. This was followed by a multiple-choice mathematical test with the 50 problems (Questionnaire IV) using the same 200 items and offering the correct and incorrect answers. In questionnaire IV, subjects tended to choose correct as well as incorrect responses corresponding to their highest hedonic rating within each problem. In all cases the subjects' behavior was higher than chance level, and thus, followed the trend to maximize pleasure.
        
        
          Conclusions
          The results of the three experiments support the hypothesis according to which decisions are made in the hedonic dimension of conscious experience.
Compound 530624: 5-Chlorovaleric acid, 2,6-dimethylnon-1-en-3-yn-5-yl ester

Chemical compound data from PubChem database. IUPAC Name: 2,6-dimethylnon-1-en-3-yn-5-yl 5-chloropentanoate. Molecular Formula: C16H25ClO2. Molecular Weight: 284.82. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.